JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Amgen Inc

Fermé

SecteurSoins de santé

329.49 1.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

320.44

Max

329.66

Chiffres clés

By Trading Economics

Revenu

-1.9B

1.3B

Ventes

339M

9.9B

P/E

Moyenne du Secteur

23.923

67.147

BPA

5.29

Rendement du dividende

2.76

Marge bénéficiaire

13.47

Employés

31,500

EBITDA

-839M

5.1B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+12.03% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.76%

2.36%

Date du Prochain Dividende

5 juin 2026

Date du Prochain Détachement de Dividende

15 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.2B

183B

Ouverture précédente

327.72

Clôture précédente

329.49

Sentiment de l'Actualité

By Acuity

18%

82%

46 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Amgen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 20:16 UTC

Résultats

Amgen Posts Higher 1Q Profit, Revenue

6 avr. 2026, 17:09 UTC

Principaux Mouvements du Marché

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 févr. 2026, 21:49 UTC

Résultats

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 janv. 2026, 15:14 UTC

Acquisitions, Fusions, Rachats

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 nov. 2025, 21:55 UTC

Principaux Mouvements du Marché

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 avr. 2026, 20:01 UTC

Résultats

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen 1Q Adj EPS $5.15 >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen 1Q Rev $8.62B >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen 1Q Net $1.82B >AMGN

30 avr. 2026, 20:01 UTC

Résultats

Amgen 1Q EPS $3.34 >AMGN

1 avr. 2026, 20:07 UTC

Acquisitions, Fusions, Rachats

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 févr. 2026, 19:56 UTC

Market Talk

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Adj EPS $5.29 >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Net $1.33B >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Rev $9.9B >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 févr. 2026, 21:01 UTC

Résultats

Amgen 4Q EPS $2.45 >AMGN

28 janv. 2026, 17:47 UTC

Résultats

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 janv. 2026, 14:01 UTC

Acquisitions, Fusions, Rachats

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 janv. 2026, 14:01 UTC

Acquisitions, Fusions, Rachats

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 janv. 2026, 14:00 UTC

Acquisitions, Fusions, Rachats

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Comparaison

Variation de prix

Amgen Inc prévision

Objectif de Prix

By TipRanks

12.03% hausse

Prévisions sur 12 Mois

Moyen 362.81 USD  12.03%

Haut 432 USD

Bas 295 USD

Basé sur 24 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

24 ratings

10

Achat

13

Maintien

1

Vente

Score Technique

By Trading Central

270.44 / 276.44Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

46 / 347Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat